| |
| |
|
| Insider
Information: |
Goodman Corey S |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
12,296,786 |
|
|
Indirect Shares
|
8,829,949 |
|
|
| Direct
Value |
$343,454,843 |
|
|
|
Indirect Value
|
$60,562,155 |
|
|
| Total
Shares |
21,126,735 |
|
|
| Total
Value |
$404,016,998 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -27.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Renovis Inc |
RNVS |
Director |
2008-05-02 |
0 |
2008-05-02 |
0 |
Premium* |
|
|
Pfizer Inc |
PFE |
Senior Vice President |
2009-02-26 |
82,232 |
2009-02-26 |
1,095 |
Premium* |
|
|
Precision Biosciences Inc |
DTIL |
10% Owner |
2019-04-01 |
0 |
2019-04-01 |
4,265,141 |
Premium* |
|
|
Akero Therapeutics, Inc. |
AKRO |
|
2019-06-24 |
0 |
2020-07-06 |
3,033,552 |
Premium* |
|
|
Alx Oncology Holdings Inc |
ALXO |
Executive Chairman, Di... |
|
0 |
2020-07-21 |
515,894 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
|
2020-09-18 |
3,059,123 |
2020-09-18 |
0 |
Premium* |
|
|
Ventyx Biosciences, Inc. |
VTYX |
See Remarks, 10% Owner |
2021-10-25 |
3,997,269 |
2021-10-25 |
1,014,267 |
Premium* |
|
|
Rayzebio, Inc. |
RYZB |
|
2023-09-19 |
5,158,162 |
2023-09-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
82 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2006-04-06 |
4 |
AS |
$20.12 |
$253,560 |
I/I |
(12,500) |
227,956 |
|
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2019-12-31 |
4 |
S |
$23.96 |
$343,259 |
I/I |
(14,324) |
3,940,534 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-01-08 |
4 |
S |
$19.86 |
$311,355 |
I/I |
(15,677) |
3,816,138 |
0 |
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2006-10-27 |
4 |
AS |
$3.52 |
$72,676 |
I/I |
(20,649) |
195,660 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-01-02 |
4 |
S |
$19.94 |
$458,507 |
I/I |
(23,000) |
3,917,534 |
0 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2008-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
24,144 |
28,253 |
0 |
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2005-06-03 |
4 |
OE |
$0.81 |
$20,250 |
D/D |
25,000 |
27,926 |
|
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2006-10-26 |
4 |
AS |
$3.74 |
$93,530 |
I/I |
(25,000) |
216,309 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-05 |
4 |
S |
$25.99 |
$743,548 |
I/I |
(28,608) |
3,239,799 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-01-07 |
4 |
S |
$20.17 |
$625,149 |
I/I |
(31,000) |
3,831,815 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-03-04 |
4 |
S |
$23.81 |
$848,766 |
I/I |
(35,650) |
3,160,319 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2008-02-08 |
4 |
D |
$2.40 |
$91,745 |
D/D |
(38,227) |
272,823 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-01-06 |
4 |
S |
$19.64 |
$829,381 |
I/I |
(42,221) |
3,862,815 |
0 |
- |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2006-04-12 |
4 |
OE |
$0.81 |
$50,563 |
I/I |
49,353 |
277,309 |
|
- |
|
| DTIL |
Precision Biosciences Inc |
10% Owner |
– – • |
2019-04-01 |
4 |
B |
$16.00 |
$800,000 |
I/I |
50,000 |
50,000 |
1.5 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2009-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
51,865 |
82,232 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-02-04 |
4 |
S |
$25.65 |
$1,378,179 |
I/I |
(53,731) |
3,268,407 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
• • • |
2020-07-01 |
4 |
S |
$34.45 |
$3,723,010 |
I/I |
(108,064) |
3,041,955 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
See Remarks |
• • • |
2020-09-18 |
4 |
B |
$13.00 |
$2,990,000 |
D/D |
230,000 |
230,000 |
0.01 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2019-06-24 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
250,000 |
1.5 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2008-05-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(272,823) |
0 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2008-05-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(285,395) |
0 |
0 |
- |
|
| VTYX |
Ventyx Biosciences, Inc. |
See Remarks |
– – • |
2021-10-25 |
4 |
B |
$16.00 |
$5,000,000 |
D/D |
312,500 |
3,997,269 |
2.45 |
% |
|
| RNVS |
Renovis Inc |
President and CEO |
• • – |
2007-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
395,000 |
403,638 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
10% Owner |
– – • |
2020-01-13 |
4 |
S |
$20.23 |
$9,993,620 |
I/I |
(494,000) |
3,322,138 |
0 |
- |
|
82 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
